Age (years)
|
63.1 ± 7.9
|
63.5 ± 8.0
|
63.2 ± 7.2
|
0.82
|
Gender (male/female), n
|
115/22
|
54/7
|
50/12
|
0.34
|
Ethnicity (Caucasian/non-Caucasian), n
|
114/23
|
53/8
|
52/10
|
0.83
|
Current smoker, n (%)
|
23 (17)
|
10 (16)
|
9 (15)
|
0.97
|
Previous smokers, n (%)
|
65 (47)
|
30 (50)
|
30 (50)
|
1.00
|
BMI (kg/m2)
|
29.2 ± 5.0
|
29.2 ± 4.0
|
29.0 ± 5.6
|
0.80
|
Waist circumference (cm)
|
106.1 ± 12.7
|
106.7 ± 11.2
|
105.3 ± 14.2
|
0.55
|
Years of diabetesb
|
9 (5, 15)
|
10 (5, 15)
|
9 (5, 13)
|
0.48
|
Microvascular complicationsc, n (%)
|
55 (40)
|
24 (39)
|
23 (37)
|
0.94
|
Hypertension, n (%)
|
100 (73)
|
45 (74)
|
46 (74)
|
1.00
|
Angina pectoris, n (%)
|
51 (37)
|
25 (41)
|
26 (42)
|
1.00
|
Previous myocardial infarction, n (%)
|
62 (45)
|
25 (41)
|
31 (50)
|
0.41
|
Years since myocardial infarctionb
|
3 (1, 11)
|
3 (1, 11)
|
3 (1, 11)
|
0.92
|
Previous PCI, n (%)
|
92 (67)
|
37 (61)
|
46 (74)
|
0.16
|
Previous CABG, n (%)
|
38 (28)
|
17 (28)
|
19 (31)
|
0.89
|
Chronic heart failure, n (%)
|
11 (8)
|
2 (3)
|
5 (8)
|
0.45
|
NYHA class II, n (%)
|
30 (22)
|
9 (15)
|
18 (29)
|
0.090
|
HbA1c (%)b
|
7.4 (6.8, 8.3)
|
7.3 (6.8, 8.3)
|
7.3 (6.8, 7.9)
|
0.90
|
Creatinine (μmol/L)b
|
79 (68, 91)
|
78 (69, 91)
|
67 (81, 88)
|
0.92
|
Medication, n (%)
|
Anti-platelet therapy
|
129 (94)
|
56 (92)
|
61 (98)
|
0.20
|
Statins
|
128 (93)
|
57 (93)
|
58 (94)
|
1.00
|
Beta-blockers
|
106 (77)
|
49 (80)
|
48 (77)
|
0.86
|
ACE-inhibitors/ARB
|
97 (70)
|
39 (64)
|
46 (74)
|
0.30
|
CCB
|
45 (33)
|
19 (31)
|
21 (34)
|
0.85
|
Metformin
|
101 (74)
|
47 (77)
|
46 (74)
|
0.87
|
Sulfonylurea
|
48 (35)
|
25 (41)
|
17 (27)
|
0.16
|
Gliptins
|
17 (12)
|
6 (10)
|
11 (18)
|
0.31
|
Insulin/insulin-analogues
|
26 (19)
|
10 (16)
|
12 (19)
|
0.85
|